| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785889 | Cancer Treatment Reviews | 2018 | 46 Pages |
Abstract
Checkpoint inhibitors represent a major advance in the treatment of advanced NSCLC and PD-L1 status can inform treatment decisions.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
B. Melosky, Q. Chu, R.A. Juergens, N. Leighl, D. Ionescu, M.-S. Tsao, D. McLeod, V. Hirsh,